Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 522 across all filing types
Latest filing 2025-01-15 Report Publication Anno…
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 99% confidence The document is titled "Publication du calendrier financier 2025" (Publication of the 2025 financial calendar) and explicitly lists future dates for key events like annual results, the General Meeting (AGM), and semi-annual results. It is a press release announcing *when* future reports and meetings will occur, rather than being the report itself (like 10-K or IR) or the AGM material (AGM-R). According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement detailing the publication schedule of other reports strongly suggests a Report Publication Announcement (RPA).
2025-01-15 French
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information relative au nombre d'actions composant le capital social et au nombre total des droits de vote" (Information relating to the number of shares comprising the share capital and the total number of voting rights). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the number of outstanding shares and the total gross and net voting rights as of December 31, 2024. This type of mandatory disclosure, focusing specifically on the total share count and voting power, is a standard regulatory filing, often related to capital structure updates or pre-AGM/voting disclosures. Since it is a direct disclosure of capital structure metrics rather than a general announcement about a future report (RPA) or a broad regulatory filing (RNS), and it deals directly with the number of shares and voting rights, it aligns most closely with 'Share Issue/Capital Change' (SHA) or potentially a specific regulatory disclosure. Given the focus on the total number of shares and voting rights, which is a fundamental aspect of capital structure reporting, SHA is the most appropriate fit among the specific options, although it is a very specific type of capital disclosure. It is not a general earnings release (ER), interim report (IR), or a director's dealing (DIRS). It is a direct disclosure of capital structure data.
2025-01-13 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that Medincell is being added to the Euronext SBF 120 index, effective December 20th. This is a general corporate announcement regarding market status and index inclusion, not a detailed financial report (like 10-K or IR), a specific regulatory filing form, or a transcript. Since it is a general announcement that doesn't fit the specific categories like DIV, DIRS, or CAP, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory or market-related announcements that aren't covered elsewhere.
2024-12-12 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release announcing that Medincell will be included in the Euronext SBF 120 Index and the CAC Mid 60 index, effective December 20, 2024. This announcement relates to the company's stock listing status and market capitalization ranking, which is a significant corporate event but does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or specific corporate actions (like DIV, CAP, DIRS). It is not an Earnings Release (ER), Interim Report (IR), Annual Report (10-K), or a Director's Dealing (DIRS). It is also not a formal announcement of a dividend (DIV) or a capital change (CAP/SHA). Since it is a general, material announcement regarding the company's market standing and visibility, and it does not fit any other specific category, the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements.
2024-12-12 English
Inside Information / Other news releases
Interim / Quarterly Report Classification · 100% confidence The document is a press release from Medincell detailing its consolidated half-year financial results for the period ending September 30, 2024. It includes comprehensive financial statements (Profit and Loss account), management commentary on financial performance, R&D portfolio updates, and strategic partnership information. Since it contains substantive financial data and analysis for a period shorter than a full fiscal year, it qualifies as an Interim/Quarterly Report. H1 2024
2024-12-10 English
Informations privilégiées / Autres communiqués
Interim / Quarterly Report Classification · 100% confidence The document is a press release titled 'Medincell publie ses résultats financiers semestriels consolidés' (Medincell publishes its consolidated half-year financial results) for the period from April 1, 2024, to September 30, 2024. It contains detailed financial statements (income statement table), management commentary on financial performance, and operational updates. Since it is a comprehensive report for a period shorter than a full fiscal year (half-year) containing actual financial statements and analysis, it is classified as an Interim/Quarterly Report. H1 2024
2024-12-10 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.